NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- State
- Under way
- Phase
- Phase 3
- People
- 377 taking part
- Started
- 18 Oct 2022
- Primary completion
- 14 Jan 2026
- Arms
- Lebrikizumab (Cohort 1), Lebrikizumab (Cohort 2)
- Results
- None posted
- 29 Sep 2022: Trial registered
- 18 Oct 2022: Trial started